Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 709 results for "Tecfidera"

Hot Biogen shares fall after Tecfidera patient dies
CNBC

Biogen Falls On Patient's Death

Biogen stock traded down 5% yesterday following the announcement that a patient administered with Tecfidera, the company's MS drug, died after developing a brain infection Page 1 of 2 Click Ticker to See live coverage Biogen Idec Inc ( ... Bidness Etc, 6 hours ago
[x]  

8 images for Tecfidera

Citybizlist, 12 hours ago
Nasdaq, 21 hours ago
Boston Globe, 20 hours ago
Boston Globe, 20 hours ago
Yahoo! News, 21 hours ago
CNBC, 22 hours ago
Reuters India, 1 day ago
Securities Technology Monitor, 23 hours ago
Boston Globe

Biogen Idec reports death of patient that had taken its multiple sclerosis pill Tecfidera

Biogen Idec Inc. said Wednesday that a patient who had taken its multiple sclerosis pill Tecfidera for more than four years died after getting a rare brain infection, sending shares of the Cambridge biotechnology company falling on the Nasdaq stock ...
 Boston Globe22 hours ago Biogen Retreats After Tecfidera Sales Miss, Patient Death Reported  TheStreet.com1 day ago Biogen shares drop on Tecfidera patient death  Town Hall1 day ago Health Exchange: Biogen shares drop on Tecfidera patient death  Austin American Statesman1 day ago
[x]  

Biogen's Tecfidera Safety Fears Overblown, but Highlight a Real Life Cycle Management Risk

We don't recognize that email. Please try again. Forgot Password? Password Please enter your password. The password you entered does not match our records. Please try again. Our records show you have a Morningstar account, but you are not ...
 Morningstar.com22 hours ago

BRIEF-Biogen confirms one case of PML in patient taking MS drug Tecfidera

Oct 22 (Reuters) - Biogen Idec Inc : * Says confirmed one case of PML in patient taking its multiple sclerosis drug Tecfidera who died of pneumonia * Says FDA been informed of PML case in Tecfidera patient who had taken drug for
 Reuters1 day ago Case of PML confirmed in someone taking Tecfidera  Noodls4 hours ago

Biogen Falls After Patient on Top-Selling Drug Dies

Shares of Biogen Idec Inc. The patient, who died from pneumonia, is the first using Tecfidera to develop the brain infection known as progressive multifocal leukoencephalopathy, or PML, Chief Executive Officer George Scangos said on a call today.
 BusinessWeek1 day ago Biogen Idec Slumps After Patient On Top-Selling Drug Dies  BioSpace15 hours ago
Gulf Times

Biogen profit surges, but Tecfidera sales shy of Street view

Oct 22 (Reuters) - Biogen Idec Inc on Wednesday reported much higher third-quarter profit and revenue, even as its big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time. Tecfidera, ...
 CNBC1 day ago Biogen profit surges; Tecfidera sales disappoint  Austin American Statesman23 hours ago Biogen Profit Surges, Tecfidera Disappoint  FOXBusiness.com1 day ago UPDATE 2-Biogen quarterly profit surges, but Tecfidera sales disappoint  CNBC1 day ago
[x]  

IPO Preview: Forward Pharma A/S

Summary Initiating a Phase 3 clinical trial for multiple sclerosis. Key competitor is Biogen. Biogen's Tecfidera® was approved by the FDA for the treatment of RRMS on March 27, 2103. Tecfidera® generated global sales of $2.08 billion from ...
 Seeking Alpha1 week ago Forward Pharma goes backward: year's largest biotech drops 17% on IPO  Nasdaq1 week ago IPO Stock Watch: Biotech Forward Pharma Falls On IPO  Investor's Business Daily1 week ago Largest Biotech IPO Yet Could Be Derailed By Forward Pharma, Biogen Idec Patent Fight  BioSpace1 week ago
[x]  
Bioresearch Online

Biogen Idec announces encouraging data from Phase III multiple sclerosis study

Biogen Idec, a biotechnology company, has announced that five-year data from the ENDORSE Phase III extension study show TECFIDERA provides sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis, or RRMS.
 Individual.com1 month ago Biogen Idec Announces Strides In Clinical Studies For MS Treatments  Bioresearch Online1 month ago
Pharma Letter

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION

PLEGRIDYTM Approved in the US and EU for Multiple Sclerosis ELOCTATETM Launched in the US for Hemophilia A Rollout of TECFIDERA® Continues across the Globe CAMBRIDGE, Mass. - Biogen Idec Inc. (NASDAQ: BIIB) today reported third quarter 2014 ...
 FiercePharma1 day ago Biogen Idec third-qtr net rockets 76% but shares slump23-10-2014  Pharma Letter4 hours ago Biogen Idec raises annual earnings guidance as third-quarter sales, profit rise  FirstWord Pharma1 day ago Biogen Idec : Third Quarter 2014 Revenues Increase 37% to $2.5 Billion  4 Traders1 day ago
[x]  

dimethyl fumarate (Tecfidera)

Pharmacy Author: Omudhome Ogbru, PharmD Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University ...
 MedicineNet.com2 months ago Biotechs Show Fed Chief's Not Much Of A Stock Analyst  Investor's Business Daily19 hours ago The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, Market Vectors Biotech ETF and PowerShares Dynamic Biotechnology & Genome Portfolio - GENOME  Yahoo! Finance2 weeks ago The Complete Guide to Biotech ETFs  Yahoo! Finance3 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less